Bone Marrow Failure and Leukemia Predisposition

Dana Farber/Boston Children's Cancer and Blood Disorders Center

The broad interest of the Shimamura laboratory is to understand the genetic and molecular mechanisms regulating hematopoiesis and clonal evolution.  We focus on bone marrow failure, myelodysplastic syndrome (MDS) and genetic cancer predisposition with the goal of identifying better diagnostic and prognostic biomarkers and developing novel therapies.  We are investigating why these disorders progress to severe aplastic anemia or leukemia.  Our lab utilizes genomics, genetics, biochemistry, cell biology, and high throughput screens using patient-derived and genomically engineered cellular models of bone marrow failure and MDS.   We have established a number of collaborations with other expert labs in the Harvard medical community.  We are striving to improve diagnosis, medical management and treatment for these patients.


See also:

Bone Marrow Failure and Myelodysplastic Syndrome Program

Shwachman Diamond Syndrome Registry